From last years full year result conference
"Mr Perreault said the focus should be on the operating profit guidance as the "indicator of underlying growth" before unpredictable items such as depreciation and amortisation on major investments, tax and the turnaround in the Novartis flu business, which CSL has combined with its existing flu business in a new unit called Seqirus."
The profit fall last year was mainly due to the loss on Seqirus.
HT1
From last years full year result conference "Mr Perreault said...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$273.51 |
Change
1.060(0.39%) |
Mkt cap ! $132.3B | |||
| Open | High | Low | Value | Volume |
| $272.45 | $274.23 | $271.02 | $81.32M | 289.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 35 | $273.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $273.52 | 347 | 19 |
View Market Depth
| Last trade - 11.32am 19/11/2024 (20 minute delay) ? |
| CSL (ASX) Chart |